Immunocytokines Market Expected To Grow Significantly At A CAGR Of 7.6% During The Forecast Period
The latest market report published by Credence Research, Inc. “Immunocytokines Market
Growth, Future Prospects, and Competitive Analysis, 2018 - 2026” the immunocytokines market is growing at a CAGR of 7.6% during the forecast period from 2018 to 2026.
Browse the full report Immunocytokines Market
Growth, Future Prospects, and Competitive Analysis, 2018 - 2026 at https://www.credenceresearch.com/report/immunocytokines-market
Immunocytokines are the molecules produced when monoclonal antibodies (tumor-reactive) link with cytokines to trigger the immune cells in a living body. The increasing prevalence of cancer and hematological malignancies globally is a major factor driving the growth of the immunocytokines market. The global market is segmented on the basis of diseases indication and targeting sites. Presently, immunocytokines are mainly utilized for treating diseases such as cancer, tumors, and rheumatoid arthritis. These molecules are usually targeting at the fat muscle, liver, B and T lymphocytes, hypothalamus, and bone marrow endothelium for treatment. Increasing investment in R&D and government for conducting clinical trials to form new molecular entities is boosting the market growth globally. Presently, the pharmaceutical organizations in the U.S. and Europe are majorly focused on conducting clinical trials for specific categories such as Interferon, tumor necrosis factor (TNF), second generation Interleukin-2, first-generation Interleukin-2, Interleukin-10, Interleukin-15, and Interleukin-12.
Advanced therapies for cancer and critical development in the production of monoclonal antibodies, antibody-drug conjugates, and immunocytokines provides better opportunities in developing nations. For e.g. cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy. Additionally, increasing demand for personalized medicines, large-scale production, changing lifestyles that habitually result in chronic diseases and the adoption of combination therapies will further spur revenue growth during the forecast period. However, unverifiable reimbursement scenario, lack of early diagnosis and treatment expensive medications, and non-availability of medications related to cancer in developing nations are the key market challenges in the global immunocytokines market.
Key Market Movements:
- Globally, the immunocytokines market remains to exhibit a profitable growth with a CAGR of 7.6% for the period from 2018 to 2026
- The development of the immunocytokines market mainly attributed to high pervasiveness of the cancer disorders along with higher output for better healthcare management
- Increasing awareness and programs held by top cancer care institutes, beneficiary reimbursement coverage for treatment, the presence of top pharmaceutical manufacturers & sophisticated healthcare infrastructure in the U.S. and Canada is contributing maximum revenue share in North America immunocytokines market
- Surging ageing population & a number of advanced healthcare settings, availability of cancer therapies and medications along increasing healthcare spending in Poland, Russia, Brazil, South Africa, India, China, and Japan contribute to overall growth of the market during the forecast period
- Major players in this vertical are Alkermes Plc, AstraZeneca Plc, CytImmune, Cytune Pharma, Altor Biosciences Corporation, Apeiron Biologics AG, Paladin Labs, Teva Pharmaceutical Industries Ltd., Valor Biotherapeutics, Targa Therapeutics Corporation, Immunomedics, Inc., ImmunGene, Inc., MolMed S.p.A., Merck KGaA, Nektar Therapeutics, Pfizer, Inc., F. Hoffmann-La Roche, Ltd. and others